Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain

NCT03865953 is registered in ClinicalTrials.gov with Lateral Pharma Pty Ltd as lead sponsor.

NCT NCT03865953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain
Lead sponsor
Lateral Pharma Pty Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2019
Completion date
May 3, 2020
Enrollment
53 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathy (dpn), neuropathic pain, post herpetic neuralgia (phn)